| Literature DB >> 27766146 |
Richard Aschbacher1, Elisabetta Pagani1, Massimo Confalonieri2, Claudio Farina3, Paolo Fazii4, Francesco Luzzaro5, Pier Giorgio Montanera6, Aurora Piazza7, Laura Pagani7.
Abstract
BACKGROUND: Rates of colonization and infection with multidrug-resistant (MDR) bacteria are increasing worldwide, in both acute care hospitals and long-term care facilities (LTCFs). Italy has one of the highest prevalence of MDR bacteria in European countries, especially with regard to methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum β-lactamase (ESBL) or carbapenemase producing Enterobacteriaceae (CPE).Entities:
Keywords: Carbapenemase; Colonization; ESBL; LTCF; MRSA
Year: 2016 PMID: 27766146 PMCID: PMC5057254 DOI: 10.1186/s13756-016-0136-1
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Colonization of European LTCF residents with MRSA and ESBL producing Enterobacteriaceae
| Country, year | Residents/LTCFs (number) | Specimen type | MRSA % (range %) | ESBL % (range %) | Referencesa |
|---|---|---|---|---|---|
| Sweden, 2008 | 495/9 | Rectal | 0.0 | 3.0 | [ |
| Sweden, 2010 | 163/1 | Catheter Urine | 0.6 | [ | |
| Sweden, 2014 | 91/10 | Rectal | 11 | [ | |
| Netherlands, 2009 | 1268/12 | Nasal | 0.3 | [ | |
| Netherlands, 2012–14 | 4763 (MRSA), 5421 (ESBL)/107 | Nasal (MRSA) Urine (ESBL, | 0.3 | 2.2 | [ |
| Germany, 2009 | 1827/32 | Nasal and/or wound | 7.6 (0–18.6) | [ | |
| Germany, 2010–11 | 240/11 | Rectal | 9.6 (0–30) | [ | |
| Germany, 2012 | 150/8 | MRSA: nasal, pharyngeal ESBL: perineal | 9.2 | 26.7 | [ |
| Germany, 2013 | 690/26 (MRSA), 455/26 (ESBL) | Nasal, pharyngeal, perineal | 6.5 | 17.8 | [ |
| Germany, 2013–14 | 2858/65 | Nasal, pharyngeal | 4.8 (0–26.7) | [ | |
| Germany, 2013–14 | 156/31 | Rectal | 14.7 | [ | |
| Luxembourg, 2010 | 954/19 | Nasal, pharyngeal | 7.2 (0–16) | [ | |
| Slovenia, 2001–02 | 107/1 | Nasal and skin | 9.3 | [ | |
| France, 2004 | 109/1 | Nasal, rectal | 37.6 | [ | |
| France, 2013 | 1155/38 | Rectal or urine | 9.9 (0.0–28.6) | [ | |
| Belgium, 2005 | 2953/60 | Nasal, pharyngeal, wound, urine | 19.5 (2.0–42.9) | [ | |
| Belgium, 2011 | 2791/60 | Nasal, pharyngeal, wound, rectal | 12.2 (0–36) | 6.2 (0–20) | [ |
| Spain, 2003 | 413/4 | Nasal, skin | 22.5 (17.2–35.5) | [ | |
| Spain, 2005 | 1377/9 | Nasal | 16.8 (6.7–35.8) | [ | |
| Spain, 2009–10 | 744/17 | Nasal | 19.6 | [ | |
| UK, 2005 | 715/39 | Nasal | 22.2 (0–50) | [ | |
| UK, 2005–07 | 3037/69 | Nasal | 20 (19–21) | [ | |
| UK, 2006–09 | 2492/65 | Nasal | 20.5 | [ | |
| Ireland, 2004–06 | 294/16 | Rectal (only | 40.5 (0–75) | [ | |
| Ireland, 2005–06 | 1111/45 | Nasal | 23.3 (0–73) | [ | |
| Ireland, 2012–13 | 64/1 | Nasal, rectal, urine | 27 | 55 | [ |
aAll studies are point prevalence studies, except three (b) that follow residents over three months [56], two years [54] or one year [4], respectively
Colonization of Italian LTCF residents and staff with MRSA and multi-drug resistant Enterobacteriaceae
| Province, year | No. of residents (R), staff (S), LTCFs (L) included | Mean age in years/female % | Specimen types | Residents, colonizationwith MDR (%) | Staff, colonization with MDR (%) | Referencesa |
|---|---|---|---|---|---|---|
| Bergamo, 2005 | R (88), S (51), L (1) | 83/80 | Nasal | MRSA (19.3) | MRSA (5.8) | [ |
| Vicenza, 2006 | R (551), L (2) | 83/73 | Nasal | MRSA (7.8) | [ | |
| Various provincesb, 2006 | R (221), L (23) | 83/61 | Catheter urine | ESBL/AmpC (54.0) | [ | |
| Bolzano, 2008c | R (111), S (69), L (1) | 84/55 | Rectal, inguinal, oro-pharyngeal, nasal, urine | ESBL (64.0) | ESBL (14.5) AmpC (1.5) | [ |
| Bolzano, 2012c | R (131), S (57), L (2) | 83/60 | Rectal, inguinal, oro-pharyngeal, nasal, urine | ESBL (49.0) | ESBL (5.2) | [ |
| Various provincesd, 2015 | R (489), L (12) | 85/69 | Rectal, nasal, axillary | ESBL (57.3) Carbapenemase KPC-3/VIM-1 (1.0) MRSA (17.2) | [ |
aAll studies are point prevalence studies; b 70 % Northern Italy, 5 % Central Italy, 25 % Southern Italy; c one of the LTCFs was screened in 2008 and 2012; carbapenemase screening was done on chromogenic ESBL agar plates; d 50 % Northern Italy, 50 % Central Italy
Characteristics of MDR Enterobacteriaceae isolated from surveillance or clinical samples of Italian LTCF residents or staff
| Italian Province, year | Bacterial species | Resistance gene (number of isolates) | Clonal group (number of isolates) | References |
|---|---|---|---|---|
| ESBL or high-level AmpC producing | ||||
| Pavia, 2003–04 |
|
| [ | |
|
| ||||
|
| ||||
| Various provinces, 2006 |
| [ | ||
|
| ||||
|
| ||||
| AmpC (3) | ||||
| Lodi, 2009–10 |
| [ | ||
|
| ||||
| Bolzano, 2012 |
| ST131 (50) | [ | |
|
| ||||
|
| ||||
|
| ||||
| Various provinces, 2006 |
|
| [ | |
|
| ||||
| Lodi, 2009–10 |
| [ | ||
| Bolzano, 2012 |
| [ | ||
|
| ||||
| Pavia, 2004–05 |
|
| [ | |
|
| ||||
| Pavia, 2003–06 | ESBL (197) | [ | ||
|
| ||||
| Various provinces, 2006 |
| [ | ||
|
| ||||
|
| ||||
|
| ||||
| Lodi, 2009–10 |
| [ | ||
|
| ||||
| Bolzano, 2012 |
| [ | ||
|
| ||||
| Various provinces, 2006 |
|
| [ | |
| Bolzano, 2012 |
| [ | ||
| Various provinces, 2015 |
| Not reported | H30-ST131 (175) | [ |
| Carbapenemase producing | ||||
| Bolzano, 2008–12 |
|
| Typing of 3 | [ |
|
|
| |||
|
|
| |||
|
|
| |||
|
|
| |||
|
|
| |||
| Bologna, 2011 |
|
| [ | |
| Milan, 2011–13 |
|
| ST131 (8) | [ |
|
| ||||
|
| ||||
| Cuneo, 2013 |
|
| H30- ST131 (1) | [ |
| Valle d’Aosta, 2013–14 |
|
| ST1789 (6) | [ |
| Various provinces, 2015 |
|
| [ | |
|
|
| |||
Risk factors for colonization of Italian and other European LTCF residents with ESBL producing Enterobacteriaceae and/or MRSA
| Risk factor | Bacterial resistance phenotype | References (Italy) | References (Other European countries) |
|---|---|---|---|
| High age | ESBL, MRSA | [ | [ |
| Male sex | ESBL, MRSA | [ | |
| Physical disability, bedridden, low functional status | ESBL, MRSA | [ | [ |
| Prolonged duration of stay in LTCF | MRSA | [ | |
| Invasive medical devices (urinary catheter, percutaneous enteral gastrostomy tube, tracheostomy tube) | ESBL, MRSA | [ | [ |
| Previous administration of antibiotics within the preceding year | ESBL, MRSA | [ | [ |
| Colonization history by the same microorganism | ESBL, MRSA | [ | |
| MDR bacteria carriage of other residents | MRSA | [ | |
| Multiple room occupancy, MDR carrier in the same room | MRSA | [ | |
| Residency in specific unit within LTCF | ESBL, MRSA | [ | |
| Prior admission to acute care hospital | ESBL, MRSA | [ | [ |
| Surgical procedures within 30 days | ESBL | [ | |
| Cancer | ESBL, MRSA | [ | [ |
| Decubitus ulcer | ESBL, MRSA | [ | [ |
| Various wounds, skin lesions | MRSA, ESBL | [ | |
| Peptic ulcer, use of antiacids | ESBL, MRSA | [ | [ |
| Chronic renal failure | ESBL | [ | |
| History of urinary tract infections | ESBL | [ | |
| Urinary and faecal incontinency | ESBL, MRSA | [ | [ |
| Chronic obstructive pulmonary disease (COPD) | ESBL, MRSA | [ | |
| Diabetes | ESBL | [ | [ |